Tag: Abilify

Compared to the last six years, compared to how intense the drugs are and how grueling the side-effects, my first psychosis at 17, I admit, was honestly not that bad.

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

From Pacific Standard: The new Abilify MyCite pill, which contains a digital sensor that tracks whether a patient has ingested the drug, has the potential...

The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.

The FDA has approved Abilify MyCite, a pill with a sensor that digitally tracks whether patients have taken their medication. "The system works by sending...

On this episode of America's Lawyer, Mike Papantonio discusses the numerous lawsuits pending involving the anti-psychotic drug Abilify, which has caused plaintiffs to develop serious...

Abilify, the antipsychotic developed by the Japanese Otsuka Group, is listed as the number four top-selling pharmaceutical, according to the influence. Article →

I have hopes for the field of psychiatry. I hope the field will redeem itself, and redeem its practitioners, because they do have clinical skill and the opportunity to learn more and grow. Many of them, I believe, were just taught bad science, influenced and infiltrated by Big Pharma.

The FDA has rejected the drug/device combination designed to monitor patient adherence with Abilify from Otsuka Pharmaceutical and Proteus Digital Health. Just last week...

Yesterday, the US Food and Drug Administration (FDA) released a warning that the antipsychotic drug aripiprazole or Abilify is associated with compulsive and uncontrollable...

The Washington Examiner reports that the manufacturer of the antipsychotic Abilify is seeking FDA approval for new digitized pills that would alert doctors if patients fail to take their drugs on schedule.

I felt a chill go through my body when I read that the FDA has agreed to review for possible approval in early 2016 a new form of the drug Abilify that contains a microchip sensor capable of sending a message that indicates the exact time a tablet dissolves in the stomach. The message is recorded by a skin patch - along with data such as the person’s body angle and activity patterns - and, according to a press release from Proteus Digital Health, the developer of the device, “this information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and only with their consent, to their physician and/or their caregivers.”

Last Thursday, the FDA agreed to review a “digital pill,” combining a sensor with the antipsychotic Abilify, in order to track patients’ compliance with drug treatment. Patients taking the tracker pill would also wear a patch, which would receive information and relay it to a mobile device, according to a brief report by BioPharmaDIVE.

This column is partly a report on the marketing of Abilify, the atypical antipsychotic that has become America’s best-selling drug.   It’s also an appeal for advice and feedback from the RxISK and Mad in America communities, and a call for some brainstorming about strategy.  The plans laid out by drugmakers Otsuka and Lundbeck for Abilify’s future, and the cooperation they’re getting from leading universities, are alarming enough to me that reporting on them seems inadequate.  We need action, although I’m not sure exactly what kind.